TriGemX Bio to go public via $160 million SPAC merger with TCGX Acquisition
TriGemX Bio, a migraine‑treatment developer, has signed a business combination agreement with TCGX Acquisition Corp. The deal includes a $160 million private‑placement at $10.00 per share and values TriGemX at a $361 million pre‑money equity. The combined company is expected to close in the first quarter of 2027, subject to shareholder and Nasdaq approvals, and will trade on Nasdaq under the ticker TGEM.
Why it matters
The transaction will provide TriGemX with capital to fund Phase 3 trials of its elismetrep migraine therapy and to prepare for a U.S. launch. Existing TCGX shareholders will see their SPAC converted into a biotech listed company, potentially affecting share price and liquidity.
Key facts
- 1The Business Combination Agreement values TriGemX at a $361 million pre‑money equity value. tradingview.com
- 2The deal includes a $160 million PIPE at $10.00 per share. tradingview.com
- 3Closing is targeted for the first quarter of 2027, subject to shareholder and Nasdaq approvals. stocktitan.net
- 4If no redemptions occur, the post‑transaction equity value is expected to be approximately $500 million. stocktitan.net
- 5The combined company will trade on Nasdaq under the ticker TGEM. lw.com
- 6TCGX expects gross proceeds of $246 million, comprising $160 million from the PIPE and $86 million held in trust. seekingalpha.com
Open questions
- Valuation figures differ across sources: $361 million pre‑money equity versus a $600 million deal value and an estimated $500 million post‑transaction equity value.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.